Loading
A phase 2 trial of camrelizumab, doxorubicin, cyclophosphamide, carboplatin and other drugs in triple-negative breast cancer, run by Blokhin's Russian Cancer Research Center, not yet recruiting.
Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT07107217 by Blokhin's Russian Cancer Research Center, with a registry enrolment figure of 40 participants, started 2025-08 and due to reach its primary completion in 2026-12. Interventions recorded: Camrelizumab; Doxorubicin +cyclophosphamide+ filgrastimum; carboplatin + paclitaxel (CP). Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "1\) 18-65 Years, female; 2) Histologically documented Triple Negative Breast Cancer (TNBC) patients; 3) Previously untreated non-metastatic (M0) TNBC, T3-4NanyM0 или TanyN+M0 3) Promising radical surgical treatment; 4) At least one measurable lesion according to RECIST 1". No results are recorded here; the registry entry is the source.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.